Here's What Caused Sarepta Therapeutics to Shoot 13% Higher In November
A month full of news related to the progress it's making toward helping patients with Duchenne muscular dystrophy (DMD) sparked a 12.9% rally in Sarepta Therapeutics (NASDAQ: SRPT) shares last month, according to S&P Global Market Intelligence.
DMD is a life-shortening, muscle-wasting disease caused by the limited or non-existent production of dystrophin, a protein important to muscle building. DMD is diagnosed in thousands of patients, and there are limited treatment options available.
Sarepta Therapeutics aims to change that.
Source: Fool.com
Sarepta Therapeutics Stock
€121.75
5.650%
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
With a target price of 130 € there is a slightly positive potential of 6.78% for Sarepta Therapeutics compared to the current price of 121.75 €.
